A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery.
Reuben
S S
SS
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000494:pharmacology*; D008159:Lumbar Vertebrae / Q000601:surgery; D008565:Membrane Proteins; D010149:Postoperative Pain / Q000517:prevention & control*; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013123:Spinal Fusion / Q000009:adverse effects*; D013449:Sulfonamides / Q000494:pharmacology*; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib